Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Payables (2020 - 2025)

Ovid Therapeutics' Payables history spans 6 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Payables fell 38.72% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 38.72%, while the annual FY2025 figure was $2.0 million, 38.72% down from the prior year.
  • Payables reached $2.0 million in Q4 2025 per OVID's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.1 million in Q4 2021 to a low of $909523.0 in Q2 2021.
  • Average Payables over 5 years is $2.9 million, with a median of $2.9 million recorded in 2021.
  • Peak YoY movement for Payables: plummeted 80.37% in 2021, then soared 407.58% in 2022.
  • A 5-year view of Payables shows it stood at $7.1 million in 2021, then crashed by 72.6% to $2.0 million in 2022, then skyrocketed by 89.61% to $3.7 million in 2023, then decreased by 13.8% to $3.2 million in 2024, then crashed by 38.72% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Payables are $2.0 million (Q4 2025), $1.7 million (Q3 2025), and $4.0 million (Q2 2025).